PMID- 32317146
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20220302
IS  - 1436-2023 (Electronic)
IS  - 0949-2658 (Print)
IS  - 0949-2658 (Linking)
VI  - 26
IP  - 2
DP  - 2021 Mar
TI  - Effect of a monocyte chemoattractant protein-1 synthesis inhibitor on fibroblasts 
      from patients with carpal tunnel syndrome.
PG  - 295-299
LID - S0949-2658(20)30081-6 [pii]
LID - 10.1016/j.jos.2020.03.010 [doi]
AB  - BACKGROUND: Carpal Tunnel Syndrome (CTS) is an idiopathic fibrotic disorder. 
      Fibrosis in the subsynovial connective tissues (SSCT) of CTS and many other 
      fibrotic diseases is mediated by Transforming growth factor beta (TGF-beta). Recently 
      monocyte chemoattractant protein-1 (MCP-1) a cytokine involved in cellular 
      recruitment has been suggested to regulate TGF-beta activity. It is related to the 
      onset of diseases which are caused by fibrosis, such as idiopathic pulmonary 
      fibrosis, renal fibrosis, and systemic scleroderma. In this study, we evaluated 
      the effect of the MCP-1 synthesis inhibitor, Bindarit, on primary cultures of 
      fibroblasts from the SSCT of five CTS patients. METHODS: Fibroblasts were treated 
      with Bindarit (10 muM, 50 muM, 100 muM, or 300 muM). Responses to inhibitors were 
      evaluated by regulation of CTS fibrosis-associated genes, fibrosis gene array and 
      Smad luciferase reporter assay. We also assessed the combination effect of 
      Bindarit and SD208, a TGF-beta receptor type 1 inhibitor on TGF-beta signaling. 
      RESULTS: Collagen type III A1 (Col3), connective tissue growth factor (CTGF), and 
      SERPINE1 expression were significantly down-regulated by Bindarit (300 muM) 
      compared to vehicle control. In the fibrosis array, expression of inhibin beta E 
      chain precursor (INHBE), beta actin (ACTB), endothelin 1 (EDN1) and hypoxanthine 
      phosphoribosyltransferase 1 (HPRT1) were significantly down-regulated, and 
      integrin beta-3 (ITGB3) was significantly up-regulated by Bindarit (300 muM). Smad 
      signal transduction activation was significantly down-regulated by Bindarit 
      (300 muM) and/or SD208 (1 muM) with TGF-beta1 compared to vehicle control with TGF-beta1. 
      CONCLUSIONS: These results suggest that Bindarit in combination with SD208 may be 
      beneficial as medical therapy for the SSCT fibrosis associated with CTS.
CI  - Copyright (c) 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. 
      All rights reserved.
FAU - Yamanaka, Yoshiaki
AU  - Yamanaka Y
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
FAU - Gingery, Anne
AU  - Gingery A
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
FAU - Oki, Gosuke
AU  - Oki G
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
FAU - Yang, Tai-Hua
AU  - Yang TH
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
FAU - Zhao, Chunfeng
AU  - Zhao C
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
FAU - Amadio, Peter C
AU  - Amadio PC
AD  - Department of Orthopedic Surgery, Biomechanics and Tendon & Soft Tissue Biology 
      Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 
      Electronic address: pamadio@mayo.edu.
LA  - eng
GR  - F32 AR063596/AR/NIAMS NIH HHS/United States
GR  - R01 AR049823/AR/NIAMS NIH HHS/United States
PT  - Journal Article
DEP - 20200419
PL  - Japan
TA  - J Orthop Sci
JT  - Journal of orthopaedic science : official journal of the Japanese Orthopaedic 
      Association
JID - 9604934
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Collagen Type III)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - *Carpal Tunnel Syndrome/drug therapy
MH  - *Chemokine CCL2/antagonists & inhibitors
MH  - Collagen Type III
MH  - Fibroblasts
MH  - Fibrosis
MH  - Humans
MH  - Transforming Growth Factor beta
MH  - Transforming Growth Factor beta1
PMC - PMC7572818
MID - NIHMS1581431
COIS- Declaration of Competing Interest None.
EDAT- 2020/04/23 06:00
MHDA- 2021/09/23 06:00
PMCR- 2022/03/01
CRDT- 2020/04/23 06:00
PHST- 2019/10/15 00:00 [received]
PHST- 2020/02/03 00:00 [revised]
PHST- 2020/03/05 00:00 [accepted]
PHST- 2020/04/23 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2020/04/23 06:00 [entrez]
PHST- 2022/03/01 00:00 [pmc-release]
AID - S0949-2658(20)30081-6 [pii]
AID - 10.1016/j.jos.2020.03.010 [doi]
PST - ppublish
SO  - J Orthop Sci. 2021 Mar;26(2):295-299. doi: 10.1016/j.jos.2020.03.010. Epub 2020 
      Apr 19.